[Results of ofloxacin treatment of experimental urinary tract infections].
The antibacterial activity of ofloxacin, a new gyrase inhibitor, was tested in experimental acute occlusive pyelonephritis in rats caused by Escherichia coli O4:H5 and Pseudomonas aeruginosa A 9532. Therapy was performed using increasing concentrations of the substance during three days. Effectiveness of therapy was investigated by determination of the bacterial counts in the tissue of kidneys and in the urine obtained by puncture of the bladder. As little as 3 X 3.75 mg/kg/day of the substance was effective and reduced the E. coli counts. The dosage of 3 X 7.5 mg/kg/day was effective in pseudomonas infections.
D000818:Animals; D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004927:Escherichia coli Infections / Q000188:drug therapy*; D005260:Female; D008826:Microbial Sensitivity Tests; D015242:Ofloxacin; D010078:Oxazines / Q000627:therapeutic use*; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011704:Pyelonephritis / Q000188:drug therapy*; D051381:Rats; D011919:Rats, Inbred Strains
D000892:Anti-Infective Agents, Urinary; D010078:Oxazines; D015242:Ofloxacin
Ofloxacin-Behandlungsergebnisse bei der experimentellen Harnwegsinfektion.